Hematology-Oncology – Page 4

Defining a Distinct Subtype of TP53-Mutated AML via BAP1 Loss: Implications for Targeted Therapy with BCL-xL Inhibitors

By MedXY 10/14/2025

Loss of the tumor suppressor BAP1 characterizes a unique subtype of TP53-mutated de novo acute myeloid leukemia (AML), correlating with poorer prognosis and erythroid lineage priming, while revealing vulnerability to BCL-xL inhibition as a promising therapeutic strategy.

Hematology-Oncology news Rheumatology

UBA6: A Novel Therapeutic Vulnerability in VEXAS Syndrome Unveiled by E1 Enzyme Dependency Profiling

By MedXY 10/14/2025

This study characterizes UBA1 mutation effects in VEXAS syndrome and identifies UBA6 as a compensatory enzyme and promising therapeutic target, highlighting selective inhibition to combat mutant hematopoietic clones.

Hematology-Oncology Rheumatology Specialties

VEXAS Anemia: Unraveling the Mosaic Erythroblastopenia in a Novel Autoinflammatory Syndrome

By MedXY 10/14/2025

This study reveals that VEXAS syndrome-associated anemia results from a mosaic erythroblastopenia due to selective UBA1 mutations in early erythroid precursors, advancing understanding of its pathophysiology and therapeutic implications.

Hematology-Oncology news Oncology

Enhancing BCMA-CAR T Cell Therapy in Multiple Myeloma Through Glutamine Metabolism Reprogramming

By MedXY 10/14/2025

Reprogramming glutamine metabolism via Asct2 transporter expression improves BCMA-CAR T cell fitness, proliferation, and anti-myeloma efficacy under glutamine-limited conditions, offering a promising strategy to overcome metabolic immune evasion in multiple myeloma.

Hematology-Oncology Specialties

Decoding Response-Adapted Daratumumab Therapy in Elderly Multiple Myeloma: Biomarkers and Mechanisms of Sensitivity and Resistance

By MedXY 10/14/2025

A response-adapted trial of daratumumab monotherapy in elderly newly diagnosed multiple myeloma reveals key biomarkers—CD38 expression, plasma cell phenotype, and immune microenvironment—that predict treatment sensitivity and inform therapeutic escalation strategies.

Hematology-Oncology Infectious Diseases news

Decoding Epstein-Barr Virus Genomic Alterations: Implications for Human Malignancies and Disease Pathogenesis

By MedXY 10/14/2025

A comprehensive genomic analysis of Epstein-Barr virus (EBV) reveals distinct single nucleotide and structural variations linked to various human diseases, especially hematological malignancies, highlighting viral mechanisms underlying pathogenesis and potential therapeutic targets.

Hematology-Oncology news

Enhancing Patient Experience in DLBCL: Insights from PROs and Clinician-Reported AEs in the Phase 3 POLARIX Trial

By MedXY 10/14/2025

The POLARIX trial demonstrates superior progression-free survival with Pola-R-CHP in untreated DLBCL, highlighting the utility of patient-reported outcomes alongside clinician-reported adverse events to capture symptom burden and quality of life comprehensively.

Hematology-Oncology news

Decoding Progression Risk in IgM-MGUS and Asymptomatic Waldenström Macroglobulinemia Through Genomic Profiling

By MedXY 10/14/2025

This article explores how genomic features differentiate stable from progressive asymptomatic Waldenström macroglobulinemia and IgM-MGUS, highlighting mutation burdens, specific gene alterations, and aneuploidy as prognostic markers for disease progression.

Hematology-Oncology news

Genetic Architecture of Myeloproliferative Neoplasm Subtypes: Uncovering a Novel Sex-Specific Association at CDH22/CD40

By MedXY 10/14/2025

A large genome-wide analysis identifies multiple genetic loci influencing MPN subtypes and reveals a female-specific variant at CDH22/CD40, enhancing understanding of disease heterogeneity and potential for personalized risk stratification.

Hematology-Oncology Oncology Specialties

Real-World Impact of Cilta-cel versus Ide-cel in CAR T-Cell Therapy for Multiple Myeloma: Insights from the German DRST Registry

By MedXY 10/14/2025

A registry analysis in Germany reveals superior remission conversion and progression-free survival with ciltacabtagene autoleucel compared to idecabtagene vicleucel in heavily pretreated multiple myeloma, supporting individualized CAR T therapy selection.

Dermatology Hematology-Oncology news

Prognostic Markers and Survival Outcomes in Advanced Mycosis Fungoides and Sézary Syndrome: Insights from the Cutaneous Lymphoma International Consortium

By MedXY 10/14/2025

A large international study identified key prognostic markers affecting survival in advanced-stage mycosis fungoides and Sézary syndrome, enabling risk stratification and guiding clinical management.

Dermatology Hematology-Oncology news

Large-Cell Transformation of Mycosis Fungoides: Clinical Patterns, Prognostic Insights, and Implications for Staging

By MedXY 10/14/2025

Large-cell transformation in mycosis fungoides marks an aggressive disease subset with distinct prognostic groups and poor survival, highlighting the need for tailored treatment and integration into staging systems.

Dermatology Hematology-Oncology news

CLIPI: A New Prognostic Index Transforming Risk Stratification in Advanced Cutaneous Lymphomas

By MedXY 10/14/2025

The CLIPI prognostic index refines risk stratification in advanced mycosis fungoides and Sézary syndrome, identifying distinct survival groups to guide personalized treatment decisions and improve outcomes.

$Genomic Insights into Pirtobrutinib Efficacy and Resistance Mechanisms in Relapsed/Refractory Chronic Lymphocytic Leukemia$

Hematology-Oncology news

Genomic Insights into Pirtobrutinib Efficacy and Resistance Mechanisms in Relapsed/Refractory Chronic Lymphocytic Leukemia

By MedXY 10/14/2025

This article explores genomic factors influencing response and resistance to pirtobrutinib, a reversible BTK inhibitor, in relapsed/refractory CLL patients previously treated with covalent BTK inhibitors, highlighting clonal mutation dynamics and resistance without clear drivers.

Hematology-Oncology

Efficacy of Rituximab Combined with Pentostatin or Bendamustine in Multiply Relapsed Hairy Cell Leukemia: Insights from a Phase 2 Trial

By MedXY 10/14/2025

This phase 2 trial reveals that both pentostatin-rituximab and bendamustine-rituximab combinations achieve high response rates exceeding rituximab alone in multiply relapsed or refractory hairy cell leukemia, with potential superiority trends favoring pentostatin-rituximab in selected patients.

Hematology-Oncology news Pediatrics

Unveiling Distinct Biological Subtypes of Chronic GVHD in Pediatric Hematopoietic Cell Transplantation: Toward Personalized Management

By MedXY 10/14/2025

Recent research identifies three unique biological subtypes of chronic graft-versus-host disease (cGvHD) in children post-hematopoietic cell transplantation, offering potential pathways for tailored treatments and improved outcomes.

Hematology-Oncology news Oncology

Circulating Tumor Cells as Prognostic Biomarkers in Transplant-Eligible Multiple Myeloma Patients Undergoing Frontline Quadruplet Therapy

By MedXY 10/14/2025

Circulating tumor cells (CTCs) serve as an independent prognostic biomarker in transplant-eligible newly diagnosed multiple myeloma patients treated with daratumumab-based quadruplet therapy, predicting progression-free survival and minimal residual disease outcomes.

Hematology-Oncology news Oncology

Busulfan-Melphalan Conditioning Enhances Outcomes in Newly Diagnosed Multiple Myeloma with Reinforced VRD: Insights from the Phase 3 GEM12 Trial

By MedXY 10/14/2025

The phase 3 GEM12 trial compares busulfan-melphalan versus melphalan conditioning in ASCT for newly diagnosed multiple myeloma, showing longer PFS with busulfan-melphalan after intensified VRD induction and consolidation, especially in advanced ISS stages and select genetic subgroups.

Hematology-Oncology news Oncology

Preclinical Progress of Glofitamab Combinations: Pioneering Therapeutics in Non-Hodgkin Lymphoma Management

By MedXY 10/14/2025

Glofitamab, a CD20×CD3 T-cell engager, demonstrates promising synergistic effects in combination with chemotherapy and novel immunotherapies, addressing resistance mechanisms in non-Hodgkin lymphoma preclinical models and supporting future clinical investigation.

Hematology-Oncology news Pediatrics

Molecular Monitoring of MRD in Pediatric AML with KMT2A::MLLT10: Prognostic Insights and Clinical Impact

By MedXY 10/14/2025

MRD monitoring by RT-qPCR in pediatric AML with KMT2A::MLLT10 fusion identifies patients at high risk despite morphologic remission, informing prognosis and guiding therapy.